Successful determination of imatinib re‐administration dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction-Reference-Cited by-同舟云学术

Successful determination of imatinib re‐administration dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction

Published:2021-08 Issue:8 Volume:9 Page:
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clin Case Rep

Author:

Nakahara Ryosuke¹^ORCID,Sumimoto Takahiro¹,Tanaka Ryota¹^ORCID,Ogata Masao²,Itoh Hiroki¹

Affiliation:

1. Department of Clinical Pharmacy Oita University Hospital Oita Japan

2. Department of Hematology Oita University Hospital Oita Japan

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.4357

Reference25 articles.

1. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

2. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

3. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

4. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

5. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hemodialysis and imatinib: Plasma levels, efficacy and tolerability in a patient with metastatic GIST - Case report;Heliyon;2024-04

2. Pharmacokinetics of Imatinib Mesylate and Development of Limited Sampling Strategies for Estimating the Area under the Concentration–Time Curve of Imatinib Mesylate in Palestinian Patients with Chronic Myeloid Leukemia;European Journal of Drug Metabolism and Pharmacokinetics;2023-11-25

3. Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients;Journal of Oncology Pharmacy Practice;2023-03-02

4. Imatinib;Reactions Weekly;2022-11-05

5. Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS;Molecules;2022-07-13